Hypochondroplasia

5 trials 3 recruiting MedDRA PT
5 Registered trials
3 Recruiting
2 Unique sponsors
2 Unique IMPs
5 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
M Musculoskeletal (ATC M) 3
Mechanism of action (INN-stem analysis)
Kinase inhibitor 1 substance
Unknown / small molecule 1 substance
Phase III: 2 Phase II/III: 1 Phase II: 2

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase III

2 trials
  • Biomarin Pharmaceutical Inc. Commercial
    VOSORITIDE
    2024-513129-22-00 4 countries 2024 n=22 Orphan
    Ended
  • Biomarin Pharmaceutical Inc. Commercial
    VOSORITIDE
    2024-517238-16-00 4 countries 2026 n=44 Orphan
    Recruiting

Phase II/III

1 trial
  • Qed Therapeutics Inc. Commercial
    INFIGRATINIB
    2024-516822-67-00 5 countries 2025 n=32
    Recruiting

Phase II

2 trials
  • Biomarin Pharmaceutical Inc. Commercial
    VOSORITIDE
    2024-512261-14-00 3 countries 2025 n=30 Orphan
    Recruiting
  • Qed Therapeutics Inc. Commercial
    INFIGRATINIB
    2025-523509-13-00 2 countries n=22 Orphan
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Biomarin Pharmaceutical Inc. Commercial 3 Phase II, Phase III 2
Qed Therapeutics Inc. Commercial 2 Phase II/III, Phase II 1
New trials by year
2024
1
2025
2
2026
1
← All indication landscapes